// App-Quantinova.ai

9504 : Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

Researchers

Presenter

  • Caroline Robert

Principal Investigators

  • Jacob Schachter

  • Ana Arance

  • Jean Jacques Grob

  • Laurent Mortier

  • Adil Daud

  • Matteo S. Carlino

  • Catriona M. McNeil

  • Michal Lotem

  • James M. G. Larkin

  • Paul Lorigan

  • Bart Neyns

  • Christian U. Blank

  • Teresa M. Petrella

  • Omid Hamid

  • Honghong Zhou

  • Blanca Homet Moreno

  • Nageatte Ibrahim

  • Antoni Ribas

Medical Centers

  • Gustave Roussy, Villejuif, France

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Aix-Marseille University, Hopital de la Timone, Marseille, France

  • Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France

  • University of California, San Francisco, San Francisco, CA

  • Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, Australia

  • Chris O'Brien Lifehouse, Camperdown, Australia

  • Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

  • The Royal Marsden Hospital, London, United Kingdom

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • Universitair Ziekenhuis, Brussels, Belgium

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Merck & Co., Inc., Kenilworth, NJ

  • University of California, Los Angeles, Los Angeles, CA

Locations

  • Canada

  • Netherlands

  • Spain

  • United Kingdom

  • Australia

  • United States

  • Israel

  • France

  • Belgium

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01866319

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved